AUB ScholarWorks

Combination of arsenic and interferon-α inhibits expression of KSHV latent transcripts and synergistically improves survival of mice with primary effusion lymphomas

Show simple item record

dc.contributor.author El Hajj H.
dc.contributor.author Ali J.
dc.contributor.author Ghantous A.
dc.contributor.author Hodroj D.
dc.contributor.author Daher A.
dc.contributor.author Zibara K.
dc.contributor.author Journo C.
dc.contributor.author Otrock Z.
dc.contributor.author Zaatari G.
dc.contributor.author Mahieux R.
dc.contributor.author El Sabban M.
dc.contributor.author Bazarbachi A.
dc.contributor.author Merhi R.A.
dc.contributor.editor
dc.date Nov-2013
dc.date.accessioned 2017-10-05T15:59:37Z
dc.date.available 2017-10-05T15:59:37Z
dc.date.issued 2013
dc.identifier 10.1371/journal.pone.0079474
dc.identifier.isbn
dc.identifier.issn 19326203
dc.identifier.uri http://hdl.handle.net/10938/19116
dc.description.abstract Background: Kaposi sarcoma-associated herpesvirus (KSHV) is the etiologic agent of primary effusion lymphomas (PEL). PEL cell lines infected with KSHV, but negative for Epstein-Barr virus have a tumorigenic potential in nonobese diabetic-severe combined immunodeficient mice and result in efficient engraftment and formation of malignant ascites with notable abdominal distension, consistent with the clinical manifestations of PEL in humans. Methodology-Principal Findings: Using this preclinical mouse model, we demonstrate that the combination of arsenic trioxide and interferon-alpha (IFN) inhibits proliferation, induces apoptosis and downregulates the latent viral transcripts LANA-1, v-FLIP and v-Cyc in PEL cells derived from malignant ascites. Furthermore, this combination decreases the peritoneal volume and synergistically increases survival of PEL mice. Conclusion-Significance: These results provide a promising rationale for the therapeutic use of arsenic-IFN in PEL patients. © 2013 El Hajj et al.
dc.format.extent
dc.language English
dc.publisher SAN FRANCISCO
dc.relation.ispartof Publication Name: PLoS ONE; Publication Year: 2013; Volume: 8; no. 11;
dc.relation.ispartofseries
dc.relation.uri
dc.source Scopus
dc.subject.other
dc.title Combination of arsenic and interferon-α inhibits expression of KSHV latent transcripts and synergistically improves survival of mice with primary effusion lymphomas
dc.type Article
dc.contributor.affiliation El Hajj, H., Department of Internal Medicine, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
dc.contributor.affiliation Ali, J., Lebanese University, Rafik Hariri Campus, Biology Department, Hadath, Lebanon
dc.contributor.affiliation Ghantous, A., International Agency for Research on Cancer, Lyon, France
dc.contributor.affiliation Hodroj, D., Lebanese University, Rafik Hariri Campus, Biology Department, Hadath, Lebanon
dc.contributor.affiliation Daher, A., Lebanese University, Rafik Hariri Campus, Biology Department, Hadath, Lebanon
dc.contributor.affiliation Zibara, K., Lebanese University, Faculty of Sciences, Biology Department, Nabatieh, Lebanon
dc.contributor.affiliation Journo, C., CIRI - International Center for Infectiology Research, Biology Department, Ecole Normale Supérieure de Lyon, Lyon, France
dc.contributor.affiliation Otrock, Z., Leukemia Program, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, United States
dc.contributor.affiliation Zaatari, G., Department of Pathology and Laboratory Medicine, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
dc.contributor.affiliation Mahieux, R., CIRI - International Center for Infectiology Research, Biology Department, Ecole Normale Supérieure de Lyon, Lyon, France
dc.contributor.affiliation El Sabban, M., Department of Anatomy, Cell Biology and Physiology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
dc.contributor.affiliation Bazarbachi, A., Department of Internal Medicine, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
dc.contributor.affiliation Merhi, R.A., Lebanese University, Rafik Hariri Campus, Biology Department, Hadath, Lebanon
dc.contributor.authorAddress Department of Internal Medicine, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Pathology and Laboratory Medicine;
dc.contributor.authorDepartment Pathology and Laboratory Medicine
dc.contributor.authorDivision
dc.contributor.authorEmail bazarbac@aub.edu.lb; raboumerhi@ul.edu.lb
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials El Hajj, H
dc.contributor.authorInitials Ali, J
dc.contributor.authorInitials Ghantous, A
dc.contributor.authorInitials Hodroj, D
dc.contributor.authorInitials Daher, A
dc.contributor.authorInitials Zibara, K
dc.contributor.authorInitials Journo, C
dc.contributor.authorInitials Otrock, Z
dc.contributor.authorInitials Zaatari, G
dc.contributor.authorInitials Mahieux, R
dc.contributor.authorInitials El Sabban, M
dc.contributor.authorInitials Bazarbachi, A
dc.contributor.authorInitials Abou Merhi, R
dc.contributor.authorOrcidID
dc.contributor.authorReprintAddress Bazarbachi, A (reprint author), Amer Univ Beirut, Fac Med, Dept Internal Med, Beirut, Lebanon.
dc.contributor.authorResearcherID
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Abou-Merhi R, 2007, LEUKEMIA, V21, P1792, DOI 10.1038-sj.leu.2404797; An J, 2004, LEUKEMIA, V18, P1699, DOI 10.1038-sj.leu.2403460; Sarosiek KA, 2010, P NATL ACAD SCI USA, V107, P13069, DOI 10.1073-pnas.1002985107; Ansari MQ, 1996, AM J CLIN PATHOL, V105, P221; Aoki Y, 2003, BLOOD, V101, P1535, DOI 10.1182-blood-2002-07-2130; Arvanitakis L, 1996, BLOOD, V88, P2648; Bazarbachi A, 1999, BLOOD, V93, P278; Bazarbachi A, 2004, LANCET ONCOL, V5, P664, DOI 10.1016-S1470-2045(04)01608-0; Boulanger E, 2003, AM J HEMATOL, V73, P143, DOI 10.1002-ajh.10341; Boulanger E, 2005, INT J CANCER, V115, P511, DOI 10.1002-ijc.20926; Cai QL, 2006, PLOS PATHOG, V2, P1002, DOI 10.1371-journal.ppat.0020116; Carbone A, 2005, J MOL DIAGN, V7, P17, DOI 10.1016-S1525-1578(10)60004-9; Carbone A, 2008, CANCER CYTOPATHOL, V114, P225, DOI 10.1002-cncr.23597; Carbone A, 1997, BRIT J HAEMATOL, V97, P515, DOI 10.1046-j.1365-2141.1997.00064.x; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056-NEJM199505043321802; Cesarman E, 1996, AM J PATHOL, V149, P53; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126-science.7997879; Chen HS, 2012, J VIROL, V86, P9454, DOI 10.1128-JVI.00787-12; Chugh P, 2005, P NATL ACAD SCI USA, V102, P12885, DOI 10.1073-pnas.0408577102; DePond W, 1997, AM J SURG PATHOL, V21, P719, DOI 10.1097-00000478-199706000-00013; El Hajj H, 2010, J EXP MED, V207, P2785, DOI 10.1084-jem.20101095; El-Sabban ME, 2000, BLOOD, V96, P2849; Fakhari FD, 2006, J CLIN INVEST, V116, P735, DOI 10.1172-JCI26190; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038-339058a0; Gessain A, 1996, BLOOD, V87, P414; Ghavamzadeh A, 2011, J CLIN ONCOL, V29, P2753, DOI 10.1200-JCO.2010.32.2107; Ghosh SK, 2003, BLOOD, V101, P2321, DOI 10.1182-blood-2002-08-2525; GIMBRONE MA, 1972, J EXP MED, V136, P261, DOI 10.1084-jem.136.2.261; GoddenKent D, 1997, J VIROL, V71, P4193; Golks A, 2006, J EXP MED, V203, P1295, DOI 10.1084-jem.20051556; Goto H, 2012, CANCER SCI, V103, P775, DOI 10.1111-j.1349-7006.2012.02212.x; Halfdanarson TR, 2006, ANN ONCOL, V17, P1849, DOI 10.1093-annonc-mdl139; Hermine O, 2004, HEMATOL J, V5, P130, DOI 10.1038-sj.thj.6200374; Hu J, 2009, P NATL ACAD SCI USA, V106, P3342, DOI 10.1073-pnas.0813280106; Huang Q, 2002, AM J SURG PATHOL, V26, P1363, DOI 10.1097-01.PAS.0000027302.89469.AB; Hussain AR, 2011, FREE RADICAL BIO MED, V50, P978, DOI 10.1016-j.freeradbiomed.2010.12.034; Ito K, 2008, NATURE, V453, P1072, DOI 10.1038-nature07016; Kchour G, 2009, BLOOD, V113, P6528, DOI 10.1182-blood-2009-03-211821; Kogan SC, 2009, CANCER CELL, V15, P7, DOI 10.1016-j.ccr.2008.12.012; Komatsu T, 2002, FRONT BIOSCI, V7, pD726, DOI 10.2741-komatsu; Koopal S, 2007, PLOS PATHOG, V3, P1348, DOI 10.1371-journal.ppat.0030140; Lacoste V, 2007, BRIT J HAEMATOL, V138, P487, DOI 10.1111-j.1365-2141.2007.06697.x; Lallemand-Breitenbach V, 2008, NAT CELL BIOL, V10, P547, DOI 10.1038-ncb1717; Lee RK, 1999, CANCER RES, V59, P5514; Lo-Coco F, 2013, NEW ENGL J MED, V369, P111, DOI 10.1056-NEJMoa1300874; Low W, 2001, J VIROL, V75, P2938, DOI 10.1128-JVI.75.6.2938-2945.2001; Lubyova B, 2007, J BIOL CHEM, V282, P31944, DOI 10.1074-jbc.M706430200; Mahieux Renaud, 2005, Leuk Lymphoma, V46, P347, DOI 10.1080-10428190400019966; Mahieux R, 2001, BLOOD, V98, P3762, DOI 10.1182-blood.V98.13.3762; Moore PS, 1996, J VIROL, V70, P549; Nador RG, 1996, BLOOD, V88, P645; Nasr R, 2003, BLOOD, V101, P4576, DOI 10.1182-blood-2002-09-2986; Nasr R, 2009, CLIN CANCER RES, V15, P6321, DOI 10.1158-1078-0432.CCR-09-0209; Nasr R, 2008, NAT MED, V14, P1333, DOI 10.1038-nm.1891; Otsuki T, 1996, LEUKEMIA, V10, P1358; Petre CE, 2007, J VIROL, V81, P1912, DOI 10.1128-JVI.01757-06; Powell BL, 2010, BLOOD, V116, P3751, DOI 10.1182-blood-2010-02-269621; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038-nm0396-342; Renne R, 2001, J VIROL, V75, P458, DOI 10.1128-JVI.75.1.458-468.2001; Riva G, 2012, BLOOD, V120, P4150, DOI 10.1182-blood-2012-04-421412; Shen ZX, 2004, P NATL ACAD SCI USA, V101, P5328, DOI 10.1073-pnas.0400053101; Simonelli C, 2003, J CLIN ONCOL, V21, P3948, DOI 10.1200-JCO.2003.06.013; Sin SH, 2007, BLOOD, V109, P2165, DOI 10.1182-blood-2006-06-028092; Song MJ, 2003, J VIROL, V77, P9451, DOI 10.1128-JVI.77.17.9451-9462.2003; SOULIER J, 1995, BLOOD, V86, P1276; Sunil Meena, 2010, Curr Infect Dis Rep, V12, P147, DOI 10.1007-s11908-010-0092-5; TOMAYKO MM, 1989, CANCER CHEMOTH PHARM, V24, P148, DOI 10.1007-BF00300234; Toomey NL, 2001, ONCOGENE, V20, P7029, DOI 10.1038-sj.onc.1204895; Uddin S, 2005, CLIN CANCER RES, V11, P3102, DOI 10.1158-1078-0432.CCR-04-1857; Verma SC, 2007, CURR TOP MICROBIOL, V312, P101; Verschuren EW, 2004, CANCER RES, V64, P581, DOI 10.1158-0008-5472.CAN-03-1863; Waddington TW, 2004, AIDS PATIENT CARE ST, V18, P67, DOI 10.1089-108729104322802498; Wang YF, 2004, ANN HEMATOL, V83, P739, DOI 10.1007-s00277-004-0949-5; Wies E, 2008, BLOOD, V111, P320, DOI 10.1182-blood-2007-05-092288; Wu W, 2005, LEUKEMIA RES, V29, P545, DOI 10.1016-j.leukres.2004.11.010; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073-pnas.94.8.3978
dc.description.citedCount 1
dc.description.citedTotWOSCount 1
dc.description.citedWOSCount 1
dc.format.extentCount 1
dc.identifier.articleNo e79474
dc.identifier.coden POLNC
dc.identifier.pubmedID 24250827
dc.identifier.scopusID 84892597027
dc.identifier.url
dc.publisher.address 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
dc.relation.ispartofConference
dc.relation.ispartofConferenceCode
dc.relation.ispartofConferenceDate
dc.relation.ispartofConferenceHosting
dc.relation.ispartofConferenceLoc
dc.relation.ispartofConferenceSponsor
dc.relation.ispartofConferenceTitle
dc.relation.ispartofFundingAgency
dc.relation.ispartOfISOAbbr PLoS One
dc.relation.ispartOfIssue 11
dc.relation.ispartOfPart
dc.relation.ispartofPubTitle PLoS ONE
dc.relation.ispartofPubTitleAbbr PLoS ONE
dc.relation.ispartOfSpecialIssue
dc.relation.ispartOfSuppl
dc.relation.ispartOfVolume 8
dc.source.ID WOS:000327216200065
dc.type.publication Journal
dc.subject.otherAuthKeyword
dc.subject.otherChemCAS arsenic trioxide, 1303-24-8, 1327-53-3, 13464-58-9, 15502-74-6
dc.subject.otherChemCAS zidovudine, 30516-87-1
dc.subject.otherIndex arsenic trioxide
dc.subject.otherIndex FLICE inhibitory protein
dc.subject.otherIndex latency associated nuclear antigen
dc.subject.otherIndex messenger RNA
dc.subject.otherIndex recombinant alpha2a interferon
dc.subject.otherIndex unclassified drug
dc.subject.otherIndex viral cyclin
dc.subject.otherIndex virus antigen
dc.subject.otherIndex virus RNA
dc.subject.otherIndex zidovudine
dc.subject.otherIndex animal experiment
dc.subject.otherIndex animal model
dc.subject.otherIndex animal tissue
dc.subject.otherIndex apoptosis
dc.subject.otherIndex article
dc.subject.otherIndex cell proliferation
dc.subject.otherIndex controlled study
dc.subject.otherIndex down regulation
dc.subject.otherIndex drug potentiation
dc.subject.otherIndex gene expression
dc.subject.otherIndex human
dc.subject.otherIndex human cell
dc.subject.otherIndex Human herpesvirus 8
dc.subject.otherIndex lymphoma cell line
dc.subject.otherIndex malignant ascites
dc.subject.otherIndex mouse
dc.subject.otherIndex NOD SCID mouse
dc.subject.otherIndex nonhuman
dc.subject.otherIndex peritoneum
dc.subject.otherIndex primary effusion lymphoma
dc.subject.otherIndex survival rate
dc.subject.otherKeywordPlus SARCOMA-ASSOCIATED HERPESVIRUS
dc.subject.otherKeywordPlus ACUTE PROMYELOCYTIC LEUKEMIA
dc.subject.otherKeywordPlus NF-KAPPA-B
dc.subject.otherKeywordPlus T-CELL LEUKEMIA
dc.subject.otherKeywordPlus MULTICENTRIC CASTLEMANS-DISEASE
dc.subject.otherKeywordPlus AIDS-RELATED LYMPHOMAS
dc.subject.otherKeywordPlus CAVITY-BASED LYMPHOMA
dc.subject.otherKeywordPlus I-TRANSFORMED-CELLS
dc.subject.otherKeywordPlus KAPOSIS-SARCOMA
dc.subject.otherKeywordPlus DNA-SEQUENCES
dc.subject.otherWOS Multidisciplinary Sciences


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


Browse

My Account